Plus Therapeutics, Inc. announced on April 15, 2025, the online availability of a new data abstract for its lead compound REYOBIQ™ in the ReSPECT-LM dose escalation trial. This data is slated for presentation at the Nuclear Medicine and Neurooncology conference in May 2025.
The abstract highlights a dose-dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space, reaching 253Gy in Cohort 5. Neuroimaging response data for 16 patients showed five (31%) with a partial response and seven with stable disease, resulting in a 75% Clinical Benefit Rate.
Clinical response based on physician evaluation showed a decrease in disease findings in 14% of evaluable patients and stable findings in 10 patients, for an 86% Clinical Benefit Rate. No dose-limiting toxicity was observed in the first four cohorts, with Grade 4 DLT in Cohorts 5 and 6.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.